ECEZ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ECEZ pulled ahead of the other in Year 1
Combined, ECEZ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ECEZ + ABBV for your $10,000?
Ecosciences, Inc. engages in the development, production, and sale of environmentally focused wastewater products to food and sanitation industries, as well as residential consumers in the United States and internationally. It produces organic tablets and powders to be used regularly and in lieu of harmful chemical cleaning products in grease trap and septic tank systems. The company provides bio-remediation services for sewers, sludge ponds, septic tanks, lagoons, farms, car washes, portable sanitation facilities, grease tanks, lakes, and ponds. Its products include Tank-Eze Wastewater Tablets, which provide active oxygen, nutrients, buffers, and safe aerobic microorganisms to clean, control odor, and keep wastewater systems running with reduced downtime; Trap-Eze Grease Trap Tablets that offer active oxygen, nutrients, buffers, and safe anaerobic and aerobic microorganisms to clean, deodorize, and keep grease traps running with reduced downtime; and Wash-Eze Car Wash Tablet, which reduces noxious odors, spotting, and other problems associated with the use of reclaimed water. The company primarily sells its products to municipalities, retail consumers, commercial and industrial users, food processors, hospitals, supermarkets, restaurants, and the janitorial supply industry through a network of master distributors, full line distributors, and sales representatives. Ecosciences, Inc. is based in Jericho, New York.
Full ECEZ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.